Content - SAKK poster sessions at ESMO 2018

SAKK poster sessions at ESMO 2018

The Congress of European Society for Medical Oncology ESMO is taking place in Munich from 19 – 23 Oct 2018.

This year, four abstracts of SAKK trials have been accepted for poster sessions:

Roger von Moos et al. (trial SAKK 96/12 / REDUSE): Prevention of symptomatic skeletal events with Denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): a non-inferiority phase III trial.

Metaxas Ioannis et al. (trial SAKK 17/16): Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma. A multicenter, single-arm, phase II Trial.

Huober Jens et al. (trial SAKK 22/10 / unicancer uc-0140/1207): Pernetta – A non comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2 positive metastatic breast cancer.

Vees Hansjörg et al. (trial SAKK 15/12): Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small-cell lung cancer. A multicenter phase II trial.

We wish the authors every success with their presentations and would like to thank everyone involved for their work.

All news